JP2024516217A5 - - Google Patents
Info
- Publication number
- JP2024516217A5 JP2024516217A5 JP2023565918A JP2023565918A JP2024516217A5 JP 2024516217 A5 JP2024516217 A5 JP 2024516217A5 JP 2023565918 A JP2023565918 A JP 2023565918A JP 2023565918 A JP2023565918 A JP 2023565918A JP 2024516217 A5 JP2024516217 A5 JP 2024516217A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- bonded
- pancreatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110482012 | 2021-04-30 | ||
| CN202110482012.2 | 2021-04-30 | ||
| PCT/CN2022/089737 WO2022228497A1 (zh) | 2021-04-30 | 2022-04-28 | 药物在治疗肿瘤疾病中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516217A JP2024516217A (ja) | 2024-04-12 |
| JP2024516217A5 true JP2024516217A5 (https=) | 2025-05-02 |
Family
ID=83846722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565918A Pending JP2024516217A (ja) | 2021-04-30 | 2022-04-28 | 腫瘍疾患の治療における医薬の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240238434A1 (https=) |
| EP (1) | EP4331614A4 (https=) |
| JP (1) | JP2024516217A (https=) |
| KR (1) | KR20240004657A (https=) |
| CN (2) | CN121490094A (https=) |
| AU (1) | AU2022263701B2 (https=) |
| BR (1) | BR112023022540A2 (https=) |
| CA (1) | CA3217111A1 (https=) |
| CL (2) | CL2023003211A1 (https=) |
| CO (1) | CO2023014715A2 (https=) |
| EC (1) | ECSP23082749A (https=) |
| GE (1) | GEAP202416383A (https=) |
| IL (1) | IL308098A (https=) |
| MX (1) | MX2023012797A (https=) |
| WO (1) | WO2022228497A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121001749A (zh) * | 2023-02-24 | 2025-11-21 | 四川科伦博泰生物医药股份有限公司 | 药物偶联物治疗肿瘤疾病的用途及方法 |
| AU2024275169A1 (en) * | 2023-05-22 | 2025-11-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Use of drug conjugate in treating tumor disease and method therefor |
| CN121443321A (zh) * | 2023-06-30 | 2026-01-30 | 默沙东有限责任公司 | 治疗组合及其用途和治疗方法 |
| WO2025209442A1 (zh) * | 2024-04-03 | 2025-10-09 | 四川科伦博泰生物医药股份有限公司 | 偶联物在治疗肿瘤疾病中的用途及方法 |
| WO2025241959A1 (zh) * | 2024-05-22 | 2025-11-27 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物在预防或治疗疾病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017257254B2 (en) * | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| WO2018192407A1 (zh) * | 2017-04-19 | 2018-10-25 | 四川科伦博泰生物医药股份有限公司 | 细胞毒素和偶联物、其用途和制备方法 |
| CN119241554A (zh) * | 2017-12-15 | 2025-01-03 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| CN110903395A (zh) * | 2018-09-14 | 2020-03-24 | 四川科伦博泰生物医药股份有限公司 | 抗体、偶联物及其制备方法和用途 |
-
2022
- 2022-04-28 EP EP22794967.4A patent/EP4331614A4/en active Pending
- 2022-04-28 WO PCT/CN2022/089737 patent/WO2022228497A1/zh not_active Ceased
- 2022-04-28 GE GEAP202416383A patent/GEAP202416383A/en unknown
- 2022-04-28 CN CN202610018019.1A patent/CN121490094A/zh active Pending
- 2022-04-28 AU AU2022263701A patent/AU2022263701B2/en active Active
- 2022-04-28 JP JP2023565918A patent/JP2024516217A/ja active Pending
- 2022-04-28 IL IL308098A patent/IL308098A/en unknown
- 2022-04-28 MX MX2023012797A patent/MX2023012797A/es unknown
- 2022-04-28 CN CN202280025989.4A patent/CN117157106A/zh active Pending
- 2022-04-28 US US18/557,900 patent/US20240238434A1/en active Pending
- 2022-04-28 KR KR1020237040823A patent/KR20240004657A/ko active Pending
- 2022-04-28 CA CA3217111A patent/CA3217111A1/en active Pending
- 2022-04-28 BR BR112023022540A patent/BR112023022540A2/pt unknown
-
2023
- 2023-10-26 CL CL2023003211A patent/CL2023003211A1/es unknown
- 2023-10-30 CO CONC2023/0014715A patent/CO2023014715A2/es unknown
- 2023-10-30 EC ECSENADI202382749A patent/ECSP23082749A/es unknown
-
2025
- 2025-03-19 CL CL2025000805A patent/CL2025000805A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516217A5 (https=) | ||
| US20250059201A1 (en) | Camptothecin compound and conjugate thereof | |
| JP2023539715A5 (https=) | ||
| EP4217398B1 (en) | Anti-c-met antibody drug conjugates | |
| JP2020509027A5 (https=) | ||
| JP2022543780A5 (https=) | ||
| JP2018537975A5 (https=) | ||
| JP2023545096A5 (https=) | ||
| US20240091374A1 (en) | Anti-sez6 antibody drug conjugates | |
| AU2022263701B2 (en) | Use of medicament in treatment of tumor disease | |
| JP2021534188A5 (https=) | ||
| CN115869325A (zh) | 化合物用于制备治疗kras突变癌症患者的药物的用途 | |
| JP2024531353A5 (https=) | ||
| CN101291675B (zh) | 抗癌组合药物 | |
| JP2024515266A5 (https=) | ||
| CN119300868B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| CN119053607B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| WO2025103379A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| JP2023531090A5 (https=) | ||
| WO2025061110A1 (zh) | 抗b7h3抗体药物偶联物在制备治疗鼻咽癌和/或肺淋巴上皮瘤样癌的药物中的用途 | |
| JP2024519449A5 (https=) | ||
| JP2024511977A5 (https=) | ||
| JP2023500385A5 (https=) | ||
| JP2025542384A5 (https=) | ||
| WO2025036307A1 (zh) | 抗frα抗体药物偶联物在治疗疾病中的应用 |